JUBLPHARMA

- Jubilant Pharmova Limited approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. - The company will also seek members' authorization via Postal Ballot for issuing debt securities up to ₹2,500 crore outstanding at any point. - NCDs have a face value of ₹1,00,000 each with a tenure of up to five years and are proposed to be listed on BSE.

- Jubilant Pharmova Limited announced the outcome of its Board Meeting held on October 12, 2026. - Approved the issuance of up to 80,000 Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. - Approved seeking members' authorization via Postal Ballot for issuing non-convertible debt securities up to an aggregate amount of ₹2,500 crore outstanding at any point.

Jubilant Pharmova's Radiopharma business announced an investment of CAD 94.5 million to modernize its Kirkland, Québec facility and double the production capacity of RUBY-FILL®. - The Government of Canada will provide financial support of CAD 23.8 million for the project through the Strategic Response Fund.

- The company has issued a specimen letter sent to physical security holders whose final dividend for FY 2025-26 has been withheld. - The withholding is due to the non-submission of mandatory KYC documents and bank details as per SEBI regulations. - Shareholders are requested to submit forms like ISR-1, ISR-2, and nomination details to the RTA to claim their dividend electronically.

- USFDA classified Jubilant HollisterStier LLC's CMO facility (Spokane, WA) as 'Voluntary Action Indicated (VAI)' following an inspection from June 8-17, 2026.

- Jubilant Pharmova received a Show Cause Notice on August 31, 2026, from the Assistant Commissioner of Commercial taxes, Mysore. - The notice demands GST, interest, and penalty totaling ₹87.31 Cr for FY 2022-23. - The Company believes the notice is incorrect, will file a detailed reply, and expects no financial or operational impact.